Royalty Pharma plc
$33.54B- Market cap
- $24.83B
- Debt
- +$9.33B
- Cash
- −$618.70M
Capital structure 73% equity / 27% debt · EV / Revenue 14.11x · EV / EBITDA 31.91x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: RPRX stock price at discount vs ICUI $63.98 current versus $9.94K implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ICUI's multiple
Implied fair value · at RPRX's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RPRX FY 2025 (ended Dec 31, 2025) · ICUI FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 73% equity / 27% debt · EV / Revenue 14.11x · EV / EBITDA 31.91x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 77% equity / 23% debt
RPRX carries the larger enterprise value at $33.54B against $5.48B; ICUI trades on the lower EV / Revenue multiple (2.45x vs 14.11x); ICUI on the lower EV / EBITDA (13.54x vs 31.91x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Royalty Pharma plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
ICU MEDICAL INC/DE · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.96x
0.60x
Net debt / EBITDA
Leverage against operating earnings
8.29x
—
Cash and equivalents
Liquid reserves on the balance sheet
$618.70M
—
Total debt
Interest-bearing obligations outstanding
$9.33B
$1.28B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.